Chemotherapy trial in paucibacillary leprosy using clofazimine

Area of Science:

• Dermatology
• Infectious Diseases
• Pharmacology

Background:

• Leprosy, a chronic infectious disease, requires effective multidrug therapy (MDT) for successful treatment.
• The World Health Organization (WHO) MDT regimen is the standard for leprosy treatment.
• Optimizing MDT regimens to improve patient outcomes and reduce relapse rates remains an important research area.

Purpose of the Study:

• To evaluate the efficacy and safety of adding clofazimine to the standard WHO MDT regimen for leprosy patients.
• To compare the treatment outcomes, including lesion activity and relapse rates, between the standard regimen and the clofazimine-supplemented regimen.

Main Methods:

• A double-blind, randomized study involving 300 leprosy patients (PB classification).
• Patients were assigned to either the standard WHO MDT (control group, n=150) or WHO MDT plus daily clofazimine (study group, n=150) for six months.
• Post-therapy follow-up was conducted on placebo for 2.5 to 3.5 years.

Main Results:

• The clofazimine-containing regimen showed a lower percentage of persisting lesion activity at therapy cessation (7.5% vs. 16% in controls).
• Spontaneous subsidence of lesion activity was significantly faster in the study group (80% vs. 30% in controls within six months).
• No relapses occurred in the study group, compared to two relapses in the control group during follow-up.

Conclusions:

• Adding daily clofazimine to the standard WHO MDT regimen is well-tolerated and enhances treatment efficacy in leprosy.
• This augmented regimen accelerates lesion healing and significantly reduces the risk of relapse.
• Clofazimine supplementation represents a valuable strategy for improving long-term leprosy management outcomes.